News About: Pharm. Affairs
Full of Chinese tourists in Jeju island, visiting pharmacies
Although the 3rd and 4th of April were days that have a relatively small number of tourists in the Jeju island since they were Sunday and Monday, Chinese tourists – also known as Youkers – could easily be seen in majo...
“Korea biosimilars are very successful, but manufacturers still need to work on dependency”
“Korean biosimilar manufacturers must raise dependent capability for them not to rely on foreign partners in a long-term. In order to do so, they must fully understand the global market and have enough investments.”
...
Price dualization for cervical cancer vaccines will be decided in April
The selection of price dualization for cervical cancer vaccines, which was planned to be finished by March, has been delayed to April.
On the 31st, the Korea Centers for Disease Control and Prevention(KCDC) announce...
Possibility of generic substitution on substitution-prohibited prescriptions with no reason
Whether it is a large, medical or small hospital, generic-substitution-prohibited prescriptions have frequently been filed.
Furthermore, generic-substitution-prohibited prescriptions having no clinical reason are tro...
Korea United Pharma succeed in registering ‘Cilostan CR’ in foreign countries
Korea United Pharma(CEO Duk-young Kang) acquired product approval of ‘Cilostan CR,’ an incrementally modified drug, from the Philippine Food and Drug Administration(PFDA).
Cilostan CR Tab, an incrementally modified...
Trending ‘biologics’ confuse patients due to complicated insurance benefit standards
Biologics, having low side effects and proved in efficacy for a long term, may nurture haters. This is because a number of patients have made complaints due to its complicated insurance benefit standards.
Biologics h...
Januvia family becomes King of ETC drugs over other antidiabetics
MSD Korea’s(CEO Dong-wook Hyun) diabetes type 2 treatments, the Januvia family has made the top of the 2015 4th quarter’s ETC market(based on the IMS’s amount of outpatient prescriptions).
The Januvia family, consist...
Countdown begins for 3rd generation lung cancer drugs among Hanmi, BI and AZ
Competed by Hanmi Pharm, Boehringer Ingelheim and AstraZeneca, launches of the 3rd generation non-small cell lung cancer treatments have begun a countdown.
According to the Ministry of Food and Drug Safety(MFDS) and...
Chronic hepatitis C treatments, Sovalid and Harvoni passes the first door
Chronic hepatitis C treatments, Sovaldi(sofosbuvir) and complex Harvoni(sofosbuvir, ledipasvir) have passed benefit adequacy evaluations.
This is a great news for the patient group damaged by the Dana Clinic crisis. ...
Will Sovaldi and Harvoni pass the first gateway for insurance benefit?
The health insurance benefit evaluation scheme of the Gilead’s hepatitis C treatments, Sovaldi(sofosbuvir) and Harvoni(sofosbuvir, ledipasvir) will finally be proposed at the Drug Benefit Deliberation Committee, Healt...
